Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 29;16(5):6003–6012. doi: 10.3892/ol.2018.9371

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018, Spandidos Publications

PMC Copyright notice

Figure 3. — Variants relevant to clinical characteristics. (A) Number of genes mutated in HBV carriers and non-carriers. (B) Gene ontology analysis revealed that genes mutated in HBV carriers were enriched in the VEGF, integrin and insulin/IGF signaling pathways (P<0.001). (C) Number of genes mutated in patients with or without cirrhosis. (D) Signaling pathway enrichment in cirrhosis patients (P<0.01). (E) Number of genes mutated in patients with normal or abnormal bilirubin levels. (F) Signaling pathway enrichment in patients with abnormal bilirubin levels (P<0.05). HBV, hepatitis B virus; VEGF, vascular endothelial growth factor; FGF, fibroblast growth factor; IGF, insulin-like growth factor; TGF, transforming growth factor.